Therapeutic targeting of noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and
long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of …

Cancer, infectious diseases, and metabolic and hereditary genetic disorders are a global
health burden affecting millions of people, with contemporary treatments offering limited …

The concepts of developing RNAs as new molecular entities for therapies have arisen again
and again since the discoveries of antisense RNAs, direct RNA-protein interactions …

Central nervous system (CNS) diseases are among the most difficult to treat, mainly
because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach …

Despite the important role of reactive oxygen species (ROS) in battling cancer, ROS
production with current approaches has been severely limited by the deficiency of oxy …

In the past decades, the striking development of cationic polypeptides and cell-penetrating
peptides (CPPs) tailored for small interfering RNA (siRNA) delivery has been fuelled by the …

Nucleic acid-based therapeutics (NBTs) are an emerging class of drugs with potential for the
treatment of a wide range of central nervous system conditions. To date, pertaining to CNS …

The potential of oligonucleotide therapeutics is undeniable as more than 15 drugs have
been approved to treat various diseases in the liver, central nervous system (CNS), and …

Antisense oligonucleotide (ASO) has emerged as a promising therapeutic approach for
treating central nervous system (CNS) disorders by modulating gene expression with high …

Autophagy, an intracellular degradation system, plays a vital role in protecting cells by
clearing damaged organelles, pathogens, and protein aggregates. Autophagy upregulation …